AACR 2024 | Developments for TILs and TCR modified cell therapy in solid tumors
Sebastian Klobuch, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses advances in tumor-infiltrating lymphocytes (TILs) and T cell receptor (TCR) modified cell therapy in oncology. Findings from a Phase III trial (NCT02278887) that compared TILs against checkpoint inhibitors in melanoma demonstrated the superiority of TILs in terms of progression-free survival (PFS), which is further exemplified by the recent approval of lifileucel in melanoma. Additional advances in TCR modified cell therapies include targeting MAGE-A4 in sarcoma. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Yeah, I think we made several progresses throughout the last years in those areas. So first, speaking of TIL, I think as we published one and a half years ago, the results of a randomized controlled trial comparing TIL therapy versus immune checkpoint therapy, ipilimumab in patients with advanced melanoma. And we saw an increased progression free survival in patients treated with TIL. I think this was one of the landmarks in the field...
Yeah, I think we made several progresses throughout the last years in those areas. So first, speaking of TIL, I think as we published one and a half years ago, the results of a randomized controlled trial comparing TIL therapy versus immune checkpoint therapy, ipilimumab in patients with advanced melanoma. And we saw an increased progression free survival in patients treated with TIL. I think this was one of the landmarks in the field. And of course the other thing was the approval of life lifileucel in February this year for of FDA. So these are, I think, really the landmark, accomplishments with TIL, Looking at the TCR therapies, they are also interesting study results coming up. For example, TCR targeting MAGE-A4 for in sarcoma patients, but also other TCR trials showing positive results. For example, a TCR targeting PRAME from Immatics also showing promising results in solid tumors. So really interesting results, and I’m curious what we will see in the future.
Read more...
